본문으로 건너뛰기
← 뒤로

TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors.

1/5 보강
Cancer cell 📖 저널 OA 42.9% 2024: 2/4 OA 2025: 7/18 OA 2026: 18/41 OA 2024~2026 2026 Vol.44(1) p. 187-202.e7
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
환자: solid tumors and is associated with worsened prognosis; however, its role in tumor immunology and immune checkpoint therapy (ICT) is unknown
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
we found the Tet2-mutant myeloid cells are abundant in the tumor microenvironment and contributed to an improved response to ICT.

Herbrich S, Chaib M, Anandhan S, Andrewes SW, Nagarajan A, Guan B

📝 환자 설명용 한 줄

Clonal hematopoiesis (CH) is detectable in upwards of 20% of patients with solid tumors and is associated with worsened prognosis; however, its role in tumor immunology and immune checkpoint therapy (

이 논문을 인용하기

↓ .bib ↓ .ris
APA Herbrich S, Chaib M, et al. (2026). TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors.. Cancer cell, 44(1), 187-202.e7. https://doi.org/10.1016/j.ccell.2025.09.011
MLA Herbrich S, et al.. "TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors.." Cancer cell, vol. 44, no. 1, 2026, pp. 187-202.e7.
PMID 41106379 ↗

Abstract

Clonal hematopoiesis (CH) is detectable in upwards of 20% of patients with solid tumors and is associated with worsened prognosis; however, its role in tumor immunology and immune checkpoint therapy (ICT) is unknown. Using a bone marrow chimera model of Tet2 CH in mice with solid tumors, we found the Tet2-mutant myeloid cells are abundant in the tumor microenvironment and contributed to an improved response to ICT. Mechanistically, Tet2 macrophages inside the tumor act as immunogenic antigen-presenting cells that more effectively cross-prime naive CD8 T cells in response to IFNγ. In human cohorts of 35,971 non-small cell lung cancer patients and 25,064 colorectal adenocarcinoma patients, TET2-mutant CH is associated with improved outcome specifically with ICT. This study proposes a role for Tet2 antigen presenting macrophages in shaping antitumor immunity and identifies TET2-mutant CH as a potential biomarker for improved response to ICT in patients with solid tumors.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

… 외 1개

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반